Sequoia Financial Advisors LLC Acquires 544 Shares of Cencora, Inc. (NYSE:COR)

Sequoia Financial Advisors LLC increased its holdings in shares of Cencora, Inc. (NYSE:COR) by 8.2% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 7,174 shares of the company’s stock after acquiring an additional 544 shares during the period. Sequoia Financial Advisors LLC’s holdings in Cencora were worth $1,612,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Swedbank AB increased its position in Cencora by 2.3% during the 3rd quarter. Swedbank AB now owns 1,394,449 shares of the company’s stock valued at $313,863,000 after buying an additional 31,104 shares in the last quarter. United Bank increased its holdings in shares of Cencora by 4.2% during the third quarter. United Bank now owns 5,601 shares of the company’s stock valued at $1,261,000 after acquiring an additional 225 shares in the last quarter. Assetmark Inc. increased its holdings in shares of Cencora by 33.8% during the third quarter. Assetmark Inc. now owns 2,536 shares of the company’s stock valued at $571,000 after acquiring an additional 641 shares in the last quarter. Prime Capital Investment Advisors LLC raised its position in shares of Cencora by 1.2% in the 3rd quarter. Prime Capital Investment Advisors LLC now owns 3,768 shares of the company’s stock worth $848,000 after purchasing an additional 46 shares during the last quarter. Finally, Oppenheimer & Co. Inc. grew its position in Cencora by 2.0% during the 3rd quarter. Oppenheimer & Co. Inc. now owns 5,850 shares of the company’s stock valued at $1,317,000 after purchasing an additional 115 shares during the last quarter. Hedge funds and other institutional investors own 97.52% of the company’s stock.

Insiders Place Their Bets

In other news, CEO Robert P. Mauch sold 4,970 shares of the firm’s stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $255.00, for a total transaction of $1,267,350.00. Following the sale, the chief executive officer now directly owns 51,070 shares in the company, valued at $13,022,850. This trade represents a 8.87 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CAO Lazarus Krikorian sold 2,000 shares of the company’s stock in a transaction on Monday, March 10th. The stock was sold at an average price of $260.06, for a total transaction of $520,120.00. Following the completion of the transaction, the chief accounting officer now directly owns 20,154 shares of the company’s stock, valued at $5,241,249.24. This represents a 9.03 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 13,648 shares of company stock worth $3,382,462 over the last quarter. 10.80% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

COR has been the subject of several recent analyst reports. Evercore ISI lifted their target price on shares of Cencora from $270.00 to $280.00 and gave the stock an “outperform” rating in a report on Thursday, February 6th. StockNews.com raised Cencora from a “hold” rating to a “buy” rating in a research report on Wednesday. Mizuho began coverage on Cencora in a research note on Wednesday, December 4th. They set an “outperform” rating and a $280.00 target price on the stock. JPMorgan Chase & Co. upped their price target on Cencora from $289.00 to $301.00 and gave the company an “overweight” rating in a report on Friday, January 24th. Finally, Wells Fargo & Company lifted their price objective on Cencora from $251.00 to $274.00 and gave the stock an “equal weight” rating in a report on Friday. Two investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $280.20.

Cencora Price Performance

NYSE COR opened at $258.09 on Friday. The company has a quick ratio of 0.54, a current ratio of 0.92 and a debt-to-equity ratio of 16.40. The firm has a market capitalization of $50.05 billion, a P/E ratio of 36.71, a PEG ratio of 1.31 and a beta of 0.51. The company has a 50-day moving average price of $247.59 and a 200-day moving average price of $239.13. Cencora, Inc. has a 52 week low of $214.77 and a 52 week high of $263.70.

Cencora (NYSE:COR) last released its quarterly earnings results on Wednesday, February 5th. The company reported $3.73 earnings per share for the quarter, topping the consensus estimate of $3.50 by $0.23. Cencora had a net margin of 0.46% and a return on equity of 328.62%. Equities research analysts anticipate that Cencora, Inc. will post 15.37 earnings per share for the current year.

Cencora Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, March 3rd. Shareholders of record on Friday, February 14th were issued a dividend of $0.55 per share. This represents a $2.20 annualized dividend and a yield of 0.85%. The ex-dividend date was Friday, February 14th. Cencora’s dividend payout ratio is presently 31.29%.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.